Valuing Biodiversity for Use in Pharmaceutical Research
"Biodiversity prospecting" has been touted as a mechanism for both discovering new pharmaceutical products and saving endangered ecosystems. It is unclear what values may arise from such activities, however. Evidence from transactions is incomplete and existing theoretical models are flawe...
Saved in:
Published in | The Journal of political economy Vol. 104; no. 1; pp. 163 - 185 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Chicago
The University of Chicago Press
01.02.1996
University of Chicago Press University of Chicago, acting through its Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | "Biodiversity prospecting" has been touted as a mechanism for both discovering new pharmaceutical products and saving endangered ecosystems. It is unclear what values may arise from such activities, however. Evidence from transactions is incomplete and existing theoretical models are flawed. We calculate an upper bound on the value of the "marginal species." Even under favorable assumptions this bound is modest. Slightly modified assumptions lead to drastically lower estimates. We extend our findings to the value of the marginal hectare of habitat and find that the incentives for habitat conservation generated by private pharmaceutical research are also, at best, very modest. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 0022-3808 1537-534X |
DOI: | 10.1086/262021 |